Beyond The Printed Page
-
CEO Advice From A 30-Year Pharma Veteran
10/18/2021
Lisa Conte, founder of Jaguar Health, shares her thoughts on becoming a biopharmaceutical company CEO, and the approach taken to create the proper corporate culture.
-
Don't Think Executing A Biopharma SPAC Is Easy
9/20/2021
Michael Byrnes, CFO at eFFECTOR Therapeutics, provides a prequel to an upcoming two-part article in Life Science Leader, with some specific recommendations for executive teams on SPACs.
-
John C. Martin, A Much-Missed Mentor And Kronos Bio Board Member
8/23/2021
Nobert Bischofberger, Ph.D., CEO of Kronos Bio, reflects on lessons learned from an important mentor and biotech icon.
-
Did You Expect It Would Take This Long To Go Public?
7/19/2021
Laura Niklason, M.D., Ph.D., cofounder and CEO of Humacyte, explains some of the science of her regenerative medicines company so to be public via a SPAC.
-
Have You Heard Of Eric Dube?
6/17/2021
A primer on what makes Eric Dube, Ph.D., CEO of Travere Therapeutics and upcoming feature in Life Science Leader, so inspirational.
-
How We Have Changed For The Better Thanks To COVID-19
5/17/2021
An interview with Mei Mei Hu, cofounder and CEO of Vaxxinity, provides an example of how COVID-19 and Zoom have enabled the seeing and showing of one another’s humanness.
-
Communicating Authentically During Times Of Crisis
4/19/2021
John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
-
A Lesson Learned The Hard Way
4/18/2021
Neil Kumar, cofounder and CEO of BridgeBio, discusses his rationale behind why employees didn’t have titles during the startup phase.
-
BridgeBio's Neil Kumar Remembers Those Humble Beginnings
4/12/2021
Neil Kumar, cofounder and CEO of BridgeBio, a company today valued at more than $10 billion, shares an embarrassing experience of the startup’s humble beginnings.
-
Why John Fowler Is Not Your Typical Biopharma CEO
4/5/2021
John Fowler’s atypical path to becoming a biopharmaceutical company cofounding CEO, began in Congress, along with a decade spent leading companies in completely different industries.